1. Scrip
  2. >>R&D

J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It

Prevention Of Severe Disease Consistent Across Geographies

 
• By Alaric DeArment

The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.

COVID-19 vaccine
J&J says there's more to its COVID-19 vaccine efficacy numbers than meets the eye. • Source: Shutterstock

Johnson & Johnson reported a significantly lower overall efficacy figure in interim data from the first Phase III trial of its single-dose vaccine against SARS-CoV-2 than those of competitors, causing widespread disappointment and concerns about its efficacy, particularly in the context of worries about a South African variant of the virus that has arrived in the US. But the company has suggested there is more than meets the eye.

The New Brunswick, NJ-based drug maker reported on 29 January data from the Phase III ENSEMBLE trial of JNJ-78436735, also known as Ad26.COV2.S. The vaccine overall was 66% effective at preventing COVID-19, including 72% efficacy in the US, 66% in Latin America and 57% in South Africa

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’